Skip to main content
. 2022 Jun 20;14(12):3031. doi: 10.3390/cancers14123031

Figure 2.

Figure 2

Patient stratification by the 2-metagene signature for loco–regional tumour control (LRC) in the PORT (A) and the PORT-C cohort (B). Comparison of LRC between PORT and PORT-C for the low-risk (C) and high-risk (D) groups as defined by the 2-metagene signature.